【视频】

Lai Xintian

Chairman of Chengdu Jinrui Foundation Biotech Co., Ltd.

"I hope that through this conference, we will seek more cooperation with international partners on the road to innovation, in a bid to accelerate the production of efficacious, safe and affordable drugs and pursue all-win cooperation." Lai Xintian, Chairman of Chengdu Jinrui Foundation Biotech Co., Ltd., expressed his expectations at the 2019 China-Japan Advanced Medical and New Drug R&D Summit and Achievements Transformation Conference on November 10.

As the head of a typical Sichuan-based innovative pharmaceutical companies, he believed that Sichuan has unparalleled advantages in the development of new drugs. "First of all, Sichuan is a resourceful place for research. There are many biotechnology and pharmaceutical research institutes, such as Sichuan University, Chengdu University of Traditional Chinese Medicine, Chengdu Medical College, etc., which take pride in their sizeable talent pools and strong research capabilities. Large-scale research hospitals that serve a large number of patients in the middle and western regions also have great advantages in clinical research and transformation of research achievements. Second, in recent years, the Sichuan Provincial Government has also provided substantial support for new drug R&D and commercialization. Under the impetus of the local government, the research institutes have attached significant importance to the transformation. A number of transformation research institutes have been established, and universities and colleges have also maintained an open policy to support the transformation."

In recent years, the convergence of AI technology and medical care has become increasingly frequent. Lai Xintian said that the development of AI has provided more convenient and efficient tools for new drug R&D and is accelerating its progress. “We are using some of the tools now that are expected to prevail in the future.” He said that AI could help analyze and integrate massive literature data, conduct high-throughput screening of compounds, discover drug targets, and predict pharmacokinetic indicators, which were the necessary links in the drug R&D process. AI has definitely saved a lot of time and costs for the researchers. “Now there are companies that have applied AI to clinical research, and provided health care data solutions for industrial organizations based on diagnosis and prescription data. We are happy to see the emergence of new technologies that can propel the development of new drugs."

Source: The Cover

© SCIMEA and The Cover